Biological Product (Except Diagnostic) Manufacturing federal obligations in FY2024

NAICS 325414 × FY2024 is a yearlyTrend join

Code 325414 and fiscal year 2024 share one cell. $13,693,050,316.21 is the USAspending.gov obligation amount on that cell. It is not pharmaceutical preparation manufacturing (325412), not medicinal and botanical manufacturing (325411), and not an outlay. The except-diagnostic parenthetical is part of the stored title; this page does not publish a diagnostic-product dollar split. This packet does not name contractors.

A near-half year-share can look like a two-year story. The FY2025 325414 cell on this slice is a different yearlyTrend row. Adding the two years here would double-count against the extract. Correlation with product headlines is not causation.

FY2024 against 325414's longer obligation book

50.9% of $26,909,109,940.38 is tagged to FY2024. Other years for NAICS 325414 remain other rows. The industry hub (/industries/325414/) is the parent without a year filter. FY2024 federal spending (/fiscal-years/2024/) is the parent without a 325414 filter.

Do not add those parents into $13,693,050,316.21. Cite the figure as obligations for NAICS 325414 in FY2024, not as invoices already settled at a named plant.

1,274 biological-product award records are extract-wide

1,274 is the Biological Product (Except Diagnostic) Manufacturing award-record count in this extract. It is not FY2024 awards, not unique vendors, and not a count of lots. This page does not divide $13,693,050,316.21 by 1,274 to invent a typical FY2024 biological-product contract.

What the 325414 FY2024 cell does not show

No outlays, no product split, no named primes, no state table. FEC filings do not fund these USAspending obligations. All industries (/industries/) and All spending ties (/ties/) hold other keys. Keep Biological Product (Except Diagnostic) Manufacturing and FY2024 on the citation.

Reading 325414's FY2024 overlay neighbors

Follow /industries/325414/ for NAICS 325414, /fiscal-years/2024/ for FY2024 across industries, /industries/ for the industry index, and /ties/ for other joins. Those URLs are larger than this yearlyTrend pair.

Reuse $13,693,050,316.21 only as Biological Product (Except Diagnostic) Manufacturing obligations in FY2024. The 1,274 award-record count stays on the industry extract. Filings remain on USAspending.gov. Keep Biological Product (Except Diagnostic) Manufacturing and FY2024 together when citing $13,693,050,316.21. NAICS 325414's extract-wide award-record count is 1,274, not a FY2024 census. Obligations of $13,693,050,316.21 are not outlays. Original filings remain on USAspending.gov for this 325414 × FY2024 pair. Do not add parent hubs into this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. The 50.9% share is $13,693,050,316.21 divided by the extract-wide $26,909,109,940.38, not a budget score. Unique recipients remain unpublished on this Biological Product (Except Diagnostic) Manufacturing FY2024 join. Agency and place-of-performance splits are omitted from this packet. Quote NAICS 325414, fiscal year 2024, and $13,693,050,316.21 in one sentence. The All industries index and All spending ties index are larger than this cell. A later USAspending ingest can restate $13,693,050,316.21 without changing the join keys. Keep Biological Product (Except Diagnostic) Manufacturing and FY2024 together when citing $13,693,050,316.21. NAICS 325414's extract-wide award-record count is 1,274, not a FY2024 census. Obligations of $13,693,050,316.21 are not outlays. Original filings remain on USAspending.gov for this 325414 × FY2024 pair. Do not add parent hubs into this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. The 50.9% share is $13,693,050,316.21 divided by the extract-wide $26,909,109,940.38, not a budget score. Unique recipients remain unpublished on this Biological Product (Except Diagnostic) Manufacturing FY2024 join. Agency and place-of-performance splits are omitted from this packet. Quote NAICS 325414, fiscal year 2024, and $13,693,050,316.21 in one sentence. The All industries index and All spending ties index are larger than this cell.

Questions

How much did biological product manufacturing obligate in FY2024?

USAspending.gov records $13,693,050,316.21 in Biological Product (Except Diagnostic) Manufacturing obligations for FY2024 under NAICS 325414. That yearlyTrend amount is not an outlay and not the $26,909,109,940.38 extract-wide total. Keep Biological Product (Except Diagnostic) Manufacturing and FY2024 on the same citation as $13,693,050,316.21.

Should I add the FY2025 325414 cell to this total?

No. FY2024 is 50.9% of NAICS 325414's $26,909,109,940.38 extract-wide total. The FY2025 325414 join on this slice is a separate yearlyTrend row. Do not add the two years. 1,274 is the industry extract award-record count, not a FY2024 headcount.

Do 1,274 awards mean 1,274 FY2024 biologic contracts?

No. 1,274 is 325414's extract-wide award-record count, not a FY2024 instrument list. Unique recipients are unpublished. Obligations of $13,693,050,316.21 are not outlays. The pair is NAICS 325414 plus FY2024. The pair is NAICS 325414 plus FY2024.

Are these outlays to named biologic makers?

No. $13,693,050,316.21 is an obligation aggregate. The packet names no contractors and publishes no outlay total. FEC donations do not fund this USAspending cell. USAspending.gov remains the source for NAICS 325414 in FY2024. The pair is NAICS 325414 plus FY2024.